探讨TIP30基因的表达对吉非替尼体外抑瘤的作用效果。方法:构建TIP30基因抑制的A549细胞,并采用靶向EGFR药物吉非替尼对TIP30基因有抑制和无抑制两组的细胞株进行处理。采用MTT法检测各组细胞生长抑制率和细胞生长情况。结果:成功构建TIP30基因抑制细胞,并在TIP30基因抑制的肺癌细胞(TIP30_Down)和正常TIP30细胞(TIP30_Normal)两组均给予1μmoL/L的EGFR抑制剂吉非替尼后,TIP30_Down细胞的生长速度明显慢于TIP30_Normal细胞(t=7.21,P0.01)。观察5d后,TIP30_Down组与TIP30_Normal组肿瘤细胞抑制率分别为83.15%±3.28%和49.8%±4.63%,两组比较有统计学差异(t=10.18,P0.01)。结论:TIP30基因上调可增加吉非替尼的体外抑瘤的敏感性,有望作为吉非替尼靶向治疗的预后指标。

Objective:To examine the effect of TIP 30 gene expression in the treatment with Gefitinib for lung cancer.Method:Constructed the TIP30 gene inhibited (down_regulated) A549 cells, we defined the cell line with TIP30 gene inhibited as TIP30_Down group, and the other group was TIP30_normal.We trea-ted the cell line in two groups with Gefitinib .We also detected the cell growth inhibited rate by MTT method . Results: We have successfully constructed the TIP 30 gene inhibited cell line in A 549 cells.After the two groups was treated by Gefitinib in 1μmoL/L, We found that cell growth speed of TIP 30_Down was slower than TIP30-Normal cells (t=7.21, P<0.01).After five days’ observation, the inhibition rates of cells in two groups were 83.15%±3.28%and 49.8%±4.63%, respectively.There was significant statistical difference between groups (t=10.18, P<0.01).Conclusion: TIP30 gene can increase the sensitivity of Gefitinib on the treatment of lung cancer cell line .

目的 探讨5-氮杂胞苷(5-Aza-dC)对结直肠癌细胞中TIP30基因表达的影响,并探讨其与氟尿嘧啶(5-Fu)敏感性的关系.方法 5-Aza-dC处理结直肠癌HCT116细胞,采用甲基化特异性PCR (MSP)方法检测TIP30基因启动子CpG岛甲基化状态,逆转录PCR检测TIP30 mRNA表达,Western blot法检测TIP30蛋白的表达,四甲基偶氮唑蓝(MTT)法检测HCT116细胞对5-Fu的敏感性.结果 未经5-Aza-dC处理的HCT116细胞中,TIP30基因启动子完全甲基化.5-Aza-dC处理HCT116细胞3d后去除5-Aza-dC,HCT116细胞TIP30基因非甲基化产物阳性,启动子去甲基化.随着5-Aza-dC去除时间的延长,HCT116细胞中TIP30基因启动子甲基化产物和非甲基化产物均为阳性,即启动子部分甲基化,部分非甲基化；去除5-Aza-dC第10天,TIP30基因启动子甲基化产物阳性,TIP30基因启动子重新甲基化.未经5-Aza-dC处理的结直肠癌HCT116细胞TIP30 mRNA和蛋白不表达.5-Aza-dC处理结直肠癌HCT116细胞3d后去除5-Aza-dC,TIP30 mRNA和蛋白表达明显增强.随着5-Aza-dC去除时间的延长,TIP30 mRNA和蛋白表达水平逐渐降低,第10天达到最低水平.在5-Aza-dC处理前、5-Aza-dC处理后去除5-Aza-dC的第0、10天,5-Fu作用于HCT116细胞的半数抑制浓度(IC50)分别为41.62、33.17和4.96 μg/ml.结论 TIP30基因表达差异可能与其启动子甲基化状态有关,且TIP30基因启动子甲基化差异与结直肠癌细胞对化疗药物的敏感性相关.

Objective To investigate the effect of 5-Aza-2''-deoxycytidine (5-Aza-dC) on TIP30 gene expression and the relationship between TIP30 expression and the sensitivity to 5-fluouracil (5-Fu) in colorectal cancer cells.Methods The methylation profile of TIP30 gene in HCT116 colorectal cancer cells was determined by methylation-specific PCR.The levels of TIP30 mRNA and protein were determined by RT-PCR and Western blot after the 5-Aza-dC treatment.MTT assay was used to detect the chemosensitivity of HCT116 cells to 5-Fu.Results TIP30 gene displayed complete DNA methylation in the HCT116 cells without 5-Aza-dC pretreatment.After the 5-Aza-dC treatment for 3 days,only demethylating PCR amplification product was detected and TIP30 gene showed DNA demethylation.With the prolongation of the time of removal of 5-Aza-dC treatment,methylated and demethylated PCR amplification products were observed and TIP30 gene displayed both DNA methylation and DNA demethylation in the colorectal cancer cells.At

目的探讨TIP30在表皮生长因子受体-2(HER-2)阳性乳腺癌患者癌组织中表达及临床意义。方法选择接受过生物化疗(曲妥珠单抗联合紫杉醇)的HER-2阳性晚期乳腺癌患者53例,采用免疫组化法检测患者癌组织中的TIP30表达,并分析其表达与患者临床病理特征及临床疗效的关系。结果 TIP30在HER-2阳性乳腺癌组织中阳性表达率为56.6%,TIP30表达与患者的年龄、病理类型、转移部位数量及雌激素受体、孕激素受体表达无关,而与功能状态评分及临床疗效相关(P均0.05)。53例患者化疗2个周期后,临床获益(CB)29例(CB率为54.7%)。30例TIP30阳性表达的患者中,CB 22例(73.3%);23例TIP30阴性表达的患者中,CB 7例(30.4%),两者CB率比较P0.05。TIP30表达阳性、阴性患者的中位无进展生存期分别为11.47、4.87个月,两者比较P0.01。结论 TIP30在HER-2阳性晚期乳腺癌患者癌组织中表达下调可能与预后不良有关,其可能作为该类患者生物化疗的疗效预测指标之一。

Objective To explore the expression of TIP 30 in epidermal growth factor receptor-2 ( HER-2 )-positive advanced breast cancer and its clinical significance. Me thods The expression of TIP30 was detected in 53 HER-2-positive advanced breast cancer tissues by immunohistochemistry .The tissues were obtained before biochemotherapy by Herceptin plus taxol ( TAX) .The relationship with clinicopathological parameters and biochemotherapy response was analyzed .Re-sults The positive expression rate of TIP30 was 56.6%in HER-2-positive advanced breast cancer tissues .There was no correlation between the expression of TIP30 protein and age, pathological pattern, metastasis, estrogen receptor (ER), and progestrone receptor ( PR) , but the expression of TIP 30 was associated with the functional status score and clinical efficacy (all P<0.05).After two cycles of biochemotherapy , the clinical benefit rate (CBR) was 54.7%.In 30 patients with positive TIP30 expression, the CBR was 73.3%(22/30), by cont

目的 探讨经颈静脉肝内门体分流术(TIPS)治疗门静脉高压并门静脉内栓子广泛形成后消化道出血的治疗效果.方法 3例急性上消化道出血患者,均经CT明确诊断为门静脉、肠系膜上静脉内(含1例脾静脉内栓子形成)广泛栓子形成,行TIPS止血治疗,将支架放置于造影所见栓子的远端.结果 TIPS治疗后,随访4～6周3例患者均未再发生出血,不适症状消失.结论 TIPS治疗门静脉高压并门静脉内广泛栓子形成后消化道出血,安全可行,疗效可靠,值得推广.

Objective To investigate the effect of transjugular intrahepatic portosystemic stent shunt (TIPS) on gastrointestinal bleeding after portal hypertension and portal vein wide embolism.Methods Three patients with acute upper gastrointestinal bleeding were diagnosed by CT with wide embolus formation in portal vein and superior mesenteric vein,of which,1 case was with spleen vein embolism formation.TIPS hemostatic treatment was applied to stop bleeding,and stents was placed where distal embolus can be observed by angiography.Results After TIPS treatment,no patients were re-bleeding during following-up periods (4-6 weeks).Uncomfortable symptoms of 3 cases were disappeared.Conclusion TIPS was a safe and effective way to treat gastrointestinal bleeding caused by portal hypertension and wide embolus formation.

目的：探讨肝癌晚期合并门静脉栓子后消化道出血的经颈静脉肝内门体静脉分流术（transjugular intrahepatic portosystemic shunt, TIPS）治疗效果。方法4例急性上消化道出血患者经CT及核磁腹部增强扫描确诊为门静脉癌栓，其中3例合并肠系膜上静脉内广泛栓子形成（含1例脾静脉内栓子形成）。行TIPS止血治疗，将支架放置于造影所见栓子的远端。结果 TIPS治疗后，3例随访4～6周、1例随访8周未再发生出血，腹部不适症状明显减轻或消失。结论 TIPS治疗肝癌并门静脉栓子形成后的急性上消化道出血，安全可行，疗效可靠，值得推广。

Objective To investigate the effect of transjugular intrahepatic portosystemic shunt (TIPS) on gastrointestinal bleed-ing due to advanced-stage hepatocellular carcinoma complicated by portal vein embolus. Methods Four patients with acute upper gastrointestinal bleeding were diagnosed with portal vein cancer embolus by contrast-enhanced CT and MRI scanning of the abdomen, of whom 3 patients were complicated by wide embolus formation in superior mesenteric vein (including 1 patient with spleen vein embolus formation). Hemostatic treatment by TIPS was undertaken and the stents were placed where distal embolus could be observed by angiogra-phy. Results After undergoing TIPS, no re-bleeding was found in 3 patients followed up for 4-6 weeks and 1 patient followed up for 8 weeks, and abdominal symptoms were obviously relieved or disappeared. Conclusions TIPS is a safe and effective way to treat gas-trointestinal bleeding due to hepatocellular carcinoma complicated by portal vein emb